Paper Details

  1. Home
  2. Paper Details

2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer.

Author: CasadevallNicole, ChastagnerPascal, Kassab-ChahmiDiana, MarchalChristian, Marec-BerardPerrine, MissetJean-Louis, Ray-CoquardIsabelle

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

The Standards, Options, and Recommendations (SOR) project, formerly managed by the French National Federation of Cancer Centers (FNCLCC) and now by the French National Cancer Institute, develops and disseminates clinical practice guidelines in oncology. In 2007, the SOR updated information regarding the use of erythropoiesis-stimulating agents (ESA) in anemic children with cancer. Updates were based on a review of the most reliable scientific data available, followed by critical appraisal by a multidisciplinary group of experts and validation by independent experts. The literature review identified four randomized trials providing reliable new information on ESA use in children. This review confirmed four points: treatment increases hemoglobin levels and decreases the need for blood transfusions; no quality-of-life or survival benefits were demonstrated; treatment does not appear to be associated with significantly more side effects; and the impact on thromboembolic events and patient quality of life remains unclear. The study concluded that systematic administration of ESA is not recommended for the prevention or treatment of anemia in pediatric cancer patients. However, treatment decisions should be made on a case-by-case basis, and the intravenous route should be preferred if treatment is considered.
Paper Details　
Original Abstract of the Article :
The Standards, Options, and Recommendations (SOR) project undertaken by the French National Federation of Cancer Centers (FNCLCC) to develop and disseminate clinical practice guidelines in oncology has now been taken over by the French National Cancer Institute. In 2007, the SOR updated the informat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/pbc.21953

データ提供：米国国立医学図書館（NLM）

Erythropoiesis-Stimulating Agents in Children with Cancer: A Camel's Perspective on Anemia

Cancer treatment, like navigating a treacherous desert, can leave patients vulnerable to a variety of health issues, including anemia. Erythropoiesis-stimulating agents (ESAs), like a refreshing oasis in the desert, are used to stimulate red blood cell production and combat anemia. This research, like a caravan sharing knowledge and experiences, explores the use of ESAs in treating anemia in children with cancer.

This review, a comprehensive assessment of available scientific data, found that ESAs can effectively increase hemoglobin levels and reduce the need for blood transfusions. However, the review also noted that there is no clear evidence that ESAs improve quality of life or survival in children with cancer. While ESAs can be beneficial, they must be used cautiously, like a camel choosing a safe water source, considering potential risks and benefits. The review highlights the importance of individualizing treatment decisions based on each patient's unique needs and circumstances.

ESAs in Pediatric Oncology: A Camel's Balanced Approach

This research provides valuable insight into the use of ESAs in treating anemia in children with cancer. It underscores the importance of balancing potential benefits with potential risks, like a camel carefully selecting a safe path through the desert. While ESAs can be a helpful tool, they should be used selectively and with careful monitoring.

Treating Children with Cancer: A Camel's Guide to Compassionate Care

Cancer treatment for children can be a challenging journey, like traversing a harsh desert. This research provides valuable information for clinicians caring for children with cancer. It's a reminder that every child is unique and requires a personalized approach to treatment, taking into account their specific needs and circumstances. It's like finding a comfortable oasis in the desert - a place where children can receive compassionate care and support.

Dr.Camel's Conclusion

This research highlights the importance of careful consideration when using ESAs in children with cancer. While these agents can be beneficial, they should be used strategically and with a focus on individual patient needs. It's a reminder that just like a camel seeking a safe and refreshing oasis in the desert, we must approach cancer treatment with a balanced and compassionate approach.

Date :
  1. Date Completed 2009-06-02
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

19229970

DOI: Digital Object Identifier

10.1002/pbc.21953

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.